SURYANARAYANA & SURESH
Chartered Accountants

INDIA

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
☎ 040-23386783/35164367
✉ suryanarayanasuresh@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors
SMS Pharmaceuticals Limited
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter and half year ended 30th September 2026 ('the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Suryanarayana & Suresh.
Chartered Accountants
F.R.No.006631S

SURYANARAYANA & SURESH ★ Hyderabad F.R.No: 006631S ★ Chartered Accountants

Muralikrishna Pinamaneni
Partner
M. No. 224319

Place: Hyderabad
Date: 04.11.2026

UDIN: 26224319ANXIKW4255

SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)

Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084,Telangana, India.

Tel: +91-40-6985 9999, Fax :+91-40-2525 9889 ; Email : complianceofficer@smspharma.com

Standalone Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter ended			Half Year ended		Year Ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from Operations	31,607.41	20,696.49	24,242.95	52,303.90	43,847.66	88,687.10
	(b) Other Income	133.92	174.44	143.39	308.36	202.70	835.38
	Total Income	31,741.33	20,870.93	24,386.34	52,612.26	44,050.36	89,522.48
2	Expenses						
	(a) Cost of Materials Consumed	16,924.26	13,572.13	10,493.83	30,496.39	25,085.37	51,687.27
	(b) Changes in Inventories	1,197.14	(2,384.73)	3,326.43	(1,187.59)	(242.40)	(2,284.17)
	(c) Manufacturing Expenses	2,479.92	1,951.54	2,573.49	4,431.46	4,546.21	9,070.22
	(d) Employee Benefits Expense	2,691.90	2,330.42	1,925.14	5,022.32	3,743.63	8,792.34
	(e) Finance Cost	573.57	549.95	573.62	1,123.52	1,157.66	2,307.56
	(f) Depreciation and Amortization Expense	1,032.48	999.08	1,002.06	2,031.56	1,977.31	3,991.93
	(g) Other Expenses	1,589.31	1,038.12	1,086.22	2,627.43	1,990.85	4,330.20
	Total Expenses - (a to g)	26,488.58	18,056.51	20,980.79	44,545.09	38,258.63	77,895.35
3	Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)	5,252.75	2,814.42	3,405.55	8,067.17	5,791.73	11,627.13
4	Exceptional items	-	-	-	-	-	-
5	Profit/(loss)Before Extraordinary Items and Tax (3-4)	5,252.75	2,814.42	3,405.55	8,067.17	5,791.73	11,627.13
6	Extraordinary Items	-	-	-	-	-	-
7	Profit/(loss) Before Tax (5-6)	5,252.75	2,814.42	3,405.55	8,067.17	5,791.73	11,627.13
8	Tax Expenses						
	(a) Current Tax relating to Current Period	1,292.00	610.00	825.00	1,902.00	1,325.00	2,598.00
	(b) Current Tax relating to Earlier Period	-	-	-	-	-	(4.69)
	(c) Deferred Tax	47.28	91.16	66.25	138.44	131.68	272.89
	Total Tax Expense	1,339.28	701.16	891.25	2,040.44	1,456.68	2,866.20
9	Net Profit / (Loss) after Tax (7-8)	3,913.47	2,113.26	2,514.30	6,026.73	4,335.05	8,760.93
10	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:						
	(i) Remeasurement gains/(losses) on defined benefit plans	(10.00)	(10.00)	(12.61)	(20.00)	(25.23)	4.43
	(ii)Income Tax effect on the above	2.52	2.52	3.17	5.04	6.35	(1.12)
	Total Other comprehensive Income/(loss),net of tax	(7.48)	(7.48)	(9.44)	(14.96)	(18.88)	3.31
11	Total Comprehensive Income (9+10)	3,905.99	2,105.78	2,504.86	6,011.77	4,316.17	8,764.24
12	Paid-up equity share capital (Face Value of Re.1/- each)	936.52	936.52	936.52	936.52	936.52	936.52
13	Other Equity excluding revaluation reserves						79,542.17
14	Earnings Per Equity Share of (Face Value of Re.1/- each) Basic / Diluted (not annualised)	4.18	2.26	2.82	6.44	4.86	9.58

SMS Pharmaceuticals Ltd. Hyderabad

Standalone Unaudited Statement of Assets and Liabilities as at 30 th September, 2026

(Rs.in Lakhs)

Sr. No.	Particulars	As at 30/09/2026 (Unaudited)	As at 31.03.2026 (Audited)
A	**ASSETS**		
1	**Non-Current Assets**		
	(a) Property, Plant and Equipment	**57,374.81**	53,121.67
	(b) Capital Work-in-Progress	**13,825.95**	11,582.43
	(c) Intangible Assets	**300.62**	279.60
	(d) Financial Assets:		
	(i) Investments	**5,310.60**	5,210.60
	(ii) Bank Balances	**401.49**	396.32
	(iii) Other Financial Assets	**716.60**	723.38
	(e) Other Non-Current Assets	**1,538.86**	3,129.24
	Sub Total :Non-Current Assets	**79,468.93**	74,443.24
2	**Current Assets**		
	(a) Inventories	**37,760.46**	35,095.33
	(b) Financial Assets		
	(i) Trade Receivables	**24,332.39**	21,587.70
	(ii) Cash and Cash Equivalents	**3,599.40**	4,578.15
	(iii) Bank Balances (Other than (ii) above)	**20.16**	19.78
	(iv) Other Financial Assets	**241.71**	344.81
	(c) Other Current Assets	**2,482.30**	2,031.03
	(d) Current Tax Asset (Net)	-	-
	Sub Total : Current Assets	**68,436.42**	63,656.80
	TOTAL ASSETS	**1,47,905.35**	1,38,100.04
B	**EQUITY AND LIABILITIES**		
1	**Equity:**		
	(a) Equity Share Capital	**936.52**	936.52
	(b) Other Equity	**85,179.32**	79,542.17
	Sub-Total -Shareholders' funds	**86,115.84**	80,478.69
	Liabilities:		
2	**Non-Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	**15,314.64**	17,164.01
	(b) Provisions	**157.52**	119.86
	(c) Deferred Tax Liabilities (net)	**5,222.21**	5,083.76
	Sub-Total -Non-Current Liabilities	**20,694.37**	22,367.63
3	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	**19,633.04**	19,340.79
	(ii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	**25.18**	24.67
	(b) Dues to Creditors Other than Micro & Small Enterprises	**17,013.33**	12,014.51
	(iii) Other Financial Liabilities	**3,875.42**	3,136.93
	(b) Provisions	**139.65**	92.46
	(c) Other Current Liabilities	**222.62**	582.87
	(d) Current Tax Liability (Net)	**185.90**	61.49
	Sub-Total - Current Liabilities	**41,095.14**	35,253.72
	TOTAL - EQUITY AND LIABILITIES	**1,47,905.35**	1,38,100.04



SMS Pharmaceuticals Limited

Standalone Statement of Cash Flow for the Half Year Ended September 30, 2026

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

S No	Particulars	for the Period Ended	
		30.09.2026 (Unaudited)	30.09.2025 (Unaudited)
A	Cash Flow from Operating Activities		
	Profit Before Tax	8,067.17	5,791.73
	Adjustments for:		
	Depreciation and Amortisation Expense	2,031.55	1,977.31
	Interest Income	(42.12)	(10.55)
	Interest on Borrowings	1,064.46	1,099.07
	Provision for Employee Benefits	69.88	(8.53)
	Amortisation of Transaction Cost on Borrowings	11.47	11.03
	Loss on Sale of Assets	0.01	-
		11,202.42	8,860.06
	Change in Operating Assets and Liabilities		
	(Increase)/Decrease in Trade Receivables	(2,744.68)	(1,819.01)
	(Increase)/Decrease in Inventories	(2,665.14)	(3,266.49)
	(Increase)/Decrease in Other Non Current Financial Assets	6.78	(24.75)
	(Increase)/Decrease in Other Non Current Asset	1,590.39	(1,112.75)
	(Increase)/Decrease in Other Current Financial Assets	96.62	782.83
	(Increase)/Decrease in Other Current Assets	(451.27)	(492.95)
	Increase/(Decrease) in Trade Payables	4,999.32	2,351.96
	Increase/(Decrease) in Other Financial Liabilities	740.76	35.81
	Increase/(Decrease) in Other Current Liabilities	(360.25)	(189.27)
		1,212.53	(3,734.62)
	Cash generated from Operations	12,414.95	5,125.44
	Income Taxes Paid	(1,777.59)	(1,037.10)
	Net Cash Inflow from Operating Activities "A"	10,637.36	4,088.34
B	Cash flow from Investing Activities		
	Purchase of Property, Plant and Equipment	(8,551.77)	(2,637.87)
	Sale of Property, Plant and Equipment	1.00	-
	Investment in Subsidiary	(100.00)	(300.00)
	Investment in Deposits	(0.39)	(0.27)
	Margin Money Deposits	(5.17)	(62.60)
	Interest Received on Margin Money Deposit	48.60	(20.77)
	Net Cash Inflow (Outflow) from Investing Activities "B"	(8,607.73)	(3,021.51)
C	Cash Flow from Financing Activities		
	Proceeds from Long Term Borrowings	-	638.69
	Repayment of Long Term Borrowings	(2,599.79)	(2,196.00)
	Proceeds from Short Term Borrowings	1,031.20	2,900.98
	Interest paid on Borrowings	(1,065.18)	(1,124.25)
	Net Proceeds from issue / conversion of Share Warrants	-	4,762.07
	Dividend Paid to Company's Shareholders	(374.61)	(354.61)
	Net Cash Inflow (Outflow) from Financing Activities "C"	(3,008.38)	4,626.88
	Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)	(978.75)	5,693.71
	Cash and Cash Equivalents at the beginning of the Financial Year	4,578.15	4,139.27
	Cash and Cash Equivalents at end of the period	3,599.40	9,832.97



Notes:

1 The above standalone un-audited financial results have been reviewed by the Audit Committee on November 04, 2026 and approved by the Board of Directors at its meeting held on November 04, 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued un modified conclusion in respect of the limited review for the quarter and six months ended September 30, 2026.

2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).

3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

4 As approved by the Members of the company at the 37th Annual General Meeting held on September 29, 2026, the company has disbursed on September 30, 2026 a dividend of Re.0.40 per equity share of Re.1/- each for the year ended March 31, 2026, aggregating to Rs.374.61 Lakhs

5 The figures have been regrouped / reclassified as necessary.

For SMS Pharmaceuticals Limited

SMS Pharmaceuticals Ltd. Hyderabad

Ramesh Babu Potluri
Chairman and Managing Director

Place: Hyderabad
Date : November 04, 2026

SURYANARAYANA & SURESH
Chartered Accountants

INDIA

Flat # C1, Millenium House, # 8-2-601/B,
Road No. 10, Near Zaheer Nagar Cross Road,
Banjara Hills, Hyderabad - 500 034.
☎ 040-23386783/35164367
✉ suryanarayanasuresh@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors
SMS Pharmaceuticals Limited
Hyderabad.

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of M/s SMS Pharmaceuticals Limited("the holding Company") and its share of the net profit after tax and other comprehensive income of its associate (the holding company and its associate hereinafter referred to as "the Group"), for the quarter and half year ended September 30, 2026 ("the Statement").The Statement is being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015").

2. This Statement, which is the responsibility of the holding company's management and has been approved by the holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

SURYANARAYANA & SURESH ★ Chartered Accountants ★ Hyderabad F.R.No: 006631S

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the share of profit/(loss) result of the following Subsidiary/Associate /Joint Venture:

   a. SMS Peptides Private Limited (Subsidiary Company)
   b. VKT Pharma Private Limited (Associate Company)
   c. SMS CoLab Private Limited (Wholly owned Subsidiary Company)
   d. Chemo SMS Enterprises SL (Joint Venture)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The consolidated financial results include the unaudited financial statements/ financial results of associate namely VKT Pharma Private Limited which have been reviewed by their auditor whose financial statements /Unaudited financial results reflect total assets of Rs. 30,231.26 lakhs as at 30th September 2026 total revenue of Rs. 3,983.24 lakhs, total net profit after tax of Rs.81.61 lakhs and total comprehensive income of Rs.84.45 lakhs for the quarter ended 30th September 2026 and total revenue of Rs. 8,675.85 lakhs, total net profit after tax of Rs.284.93 lakhs and total comprehensive income of Rs.290.55 lakhs for the Half year ended 30th September 2026.

8. The consolidated financial results include the unaudited financial statements/ financial results of Subsidiary namely M/s SMS Peptides Private Limited which have been reviewed by their auditor whose financial statements / Unaudited financial results reflect total assets of Rs. 731.77 lakhs as at 30th September 2026 total revenue of Rs. 1.53 lakhs, total net Loss after tax of Rs.91.09 lakhs and total comprehensive Loss of Rs.76.82 lakhs for the quarter ended 30th September 2026 and total revenue of Rs. 1.53 lakhs, total net Loss after tax of Rs.93.79 lakhs and total comprehensive Loss of Rs.78.82 lakhs for the Half year ended 30th September 2026.

9. The consolidated financial results include the unaudited financial statements/ financial results of Subsidiary namely M/s SMS CoLab Private Limited which have been reviewed by their auditor whose financial statements / Unaudited financial results

SURYANARAYANA & SURESH ★ Chartered Accountants ★ Hyderabad F.R.No: 006631S

reflect total assets of Rs. 0.71 lakhs as at 30th September 2026 total revenue of Rs. 0.00 lakhs, total net Loss after tax of Rs.0.36 lakhs and total comprehensive Loss of Rs.0.27 lakhs for the quarter ended 30th September 2026 and total revenue of Rs. 0.00 lakhs, total net Loss after tax of Rs.0.56 lakhs and total comprehensive Loss of Rs.0.42 lakhs for the Half year ended 30th September 2026.

10. The consolidated financial result also includes the unaudited financial results of joint venture namely M/s Chemo SMS Enterprises SL in which there is no operations during the quarter ended September 30, 2026. Hence, there is no significant effect on the financial statements and not material to the group.

11. Our conclusion on the Statement is not modified in respect of the above matters.

For Suryanarayana & Suresh
Chartered Accountants
F.R.No.006631S



Muralikrishna Pinamaneni
Partner
M. No. 224319

Place: Hyderabad
Date: 04.11.2026

UDIN: 26224319ENGKWY8707

SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)

Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084,Telangana, India.

Tel: +91-40-6985 9999, Fax :+91-40-2525 9889 ; Email : complianceofficer@smspharma.com

Consolidated Statement of Unaudited Financial Results for the Quarter and Half year Ended 30th September, 2026

(Rs. In Lakhs)

S.No	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from Operations	31,608.93	20,696.49	24,242.95	52,305.42	43,847.66	88,687.10
	(b) Other Income	133.92	174.44	143.39	308.36	202.70	835.38
	Total Income	31,742.85	20,870.93	24,386.34	52,613.78	44,050.36	89,522.48
2	Expenses						
	(a) Cost of Materials Consumed	16,807.65	13,664.68	10,499.26	30,472.33	25,027.87	51,643.79
	(b) Changes in Inventories	1,237.12	(2,412.93)	3,319.24	(1,175.81)	(249.59)	(2,309.48)
	(c) Manufacturing Expenses	2,480.08	1,951.60	2,573.49	4,431.68	4,546.21	9,070.22
	(d) Employee Benefits Expense	2,725.58	2,354.02	1,925.14	5,079.60	3,743.63	8,795.56
	(e) Finance Cost	573.57	549.95	573.62	1,123.52	1,157.66	2,307.56
	(f) Depreciation and Amortization Expense	1,044.16	999.08	1,002.06	2,043.24	1,977.31	3,991.93
	(g) Other Expenses	1,592.94	1,044.03	1,089.35	2,636.97	2,006.19	4,359.14
	Total Expenses - (a to g)	26,461.10	18,150.43	20,982.16	44,611.53	38,209.28	77,858.72
3	Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2)	5,281.75	2,720.50	3,404.18	8,002.25	5,841.08	11,663.76
4	Exceptional items	-	-	-	-	-	-
5	Profit/(loss)Before Extraordinary Items and Tax (3-4)	5,281.75	2,720.50	3,404.18	8,002.25	5,841.08	11,663.76
6	Extraordinary Items	-	-	-	-	-	-
7	Profit/(loss) Before Tax (5-6)	5,281.75	2,720.50	3,404.18	8,002.25	5,841.08	11,663.76
8	Tax Expenses						
	(a) Current Tax relating to Current Period	1,292.00	610.00	825.00	1,902.00	1,325.00	2,598.00
	(b) Current Tax relating to Earlier Period	-	-	-	-	-	(4.69)
	(c) Deferred Tax	32.92	90.40	66.25	123.32	131.68	270.66
	Total Tax Expense	1,324.92	700.40	891.25	2,025.32	1,456.68	2,863.97
9	Net Profit / (Loss) after Tax (7-8)	3,956.83	2,020.10	2,512.93	5,976.93	4,384.40	8,799.79
10	Share of Profit/(Loss) in Associate,net of tax	28.42	70.80	18.34	99.22	195.92	1,399.12
11	Net Profit /(loss) after taxes and share of profit/(loss) from associate (9+10)	3,985.25	2,090.90	2,531.27	6,076.15	4,580.32	10,198.91

SMS Pharmaceuticals Ltd. Hyderabad

12	**Other Comprehensive Income (OCI):**						
	Items that will not be reclassified to Profit & Loss						
	(i)Remeasurement Gain / (Loss) of the defined benefit plans	**(10.00)**	(10.00)	(12.61)	**(20.00)**	(25.23)	4.43
	(ii)Income Tax effect on the above	**2.52**	2.52	3.17	**5.04**	6.35	(1.12)
	(iii) Share of Other Comprehensive Income in Associates	**1.32**	1.30	0.88	**2.62**	1.75	9.12
	(iv)Share of Income Tax effect on the above in Associates	**(0.32)**	(0.32)	(0.23)	**(0.64)**	(0.45)	(2.37)
	Total Other comprehensive Income/(loss),net of tax	(6.48)	(6.50)	(8.79)	**(12.98)**	(17.58)	10.06
13	**Total comprehensive Income (11+12)**	**3,978.77**	2,084.40	2,522.48	**6,063.17**	4,562.74	10,208.97
14	Profit / (Loss) Attributable to						
	Shareholders of the Company	**3,985.26**	2,090.90	2,531.27	**6,076.16**	4,580.32	10,198.91
	Non-Controlling Interests	**(0.01)**	0.00	(0.00)	**(0.01)**	(0.00)	(0.00)
		3,985.25	2,090.90	2,531.27	**6,076.15**	4,580.32	10,198.91
15	Other Comprehensive Income/(Loss) Attributable to						
	Shareholders of the Company	**(6.49)**	(6.50)	(8.79)	**(12.99)**	(17.59)	10.06
	Non-Controlling Interests	-	-	-	-	-	-
		(6.49)	(6.50)	(8.79)	**(12.99)**	(17.59)	10.06
16	Total comprehensive income attributable to:						
	Shareholders of the Company	**3,978.78**	2,084.40	2,522.48	**6,063.18**	4,562.74	10,208.97
	Non-Controlling Interests	**(0.01)**	0.00	(0.00)	**(0.01)**	(0.00)	(0.00)
		3,978.77	2,084.40	2,522.48	**6,063.17**	4,562.73	10,208.97
17	Paid-up equity share capital (Face Value of Re.1/- each)	**936.52**	936.52	936.52	**936.52**	936.52	936.52
18	Other Equity excluding revaluation reserve						77,644.36
19	Earnings Per Equity Share of (Face Value of Re.1/- each) Basic / Diluted (not annualised)	**4.26**	2.23	2.84	**6.49**	5.13	**11.15**

SMS Pharmaceuticals Ltd. Hyderabad

Consolidated Unaudited Statement of Assets and Liabilities as at 30th September, 2026

(Rs.in Lakhs)

Sr. No.	Particulars	As at 30/09/2026 (Unaudited)	As at 31/03/2026 (Audited)
A	**ASSETS**		
1	**Non-Current Assets**		
	(a) Property, Plant and Equipment	57,947.33	53,121.67
	(b) Capital Work-in-Progress	13,825.95	12,164.17
	(c) Intangible Assets	303.04	279.60
	(d) Financial Assets:		
	(i) Investments	2,758.98	2,628.34
	(ii) Bank Balances	401.49	396.32
	(iii) Other Financial Assets	716.70	723.48
	(e) Other Non-Current Assets	1,538.86	3,129.24
	Sub Total :Non-Current Assets	77,492.35	72,442.82
2	**Current Assets**		
	(a) Inventories	37,773.99	35,120.64
	(b) Financial Assets		
	(i) Trade Receivables	24,329.30	21,586.62
	(ii) Cash and Cash Equivalents	3,611.11	4,587.70
	(iii) Bank Balances (Other than (ii) above)	20.16	19.78
	(iv) Other Financial Assets	241.71	344.81
	(c) Other Current Assets	2,596.18	2,141.55
	(d) Current Tax Asset (Net)	-	-
	Sub Total : Current Assets	68,572.45	63,801.10
	TOTAL ASSETS	1,46,064.80	1,36,243.92
B	**EQUITY AND LIABILITIES**		
1	**Equity:**		
	(a) Equity Share Capital	936.52	936.52
	(b) Other Equity	83,332.93	77,644.36
		84,269.45	78,580.88
	Attributable to owners of the Company		
	Non -Controlling Interest	0.00	0.01
	Sub-Total -Shareholders' funds	84,269.45	78,580.89
	Liabilities:		
2	**Non-Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	15,314.64	17,164.01
	(b) Provisions	157.52	119.86
	(c) Deferred Tax Liabilities (net)	5,204.84	5,081.53
	Sub-Total -Non-Current Liabilities	20,677.00	22,365.40
3	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	19,633.04	19,340.79
	(ii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	25.18	24.67
	(b) Dues to Creditors Other than Micro & Small Enterprises	17,021.16	12,018.69
	(iii) Other Financial Liabilities	3,889.68	3,176.55
	(b) Provisions	139.65	92.46
	(c) Other Current Liabilities	223.74	582.98
	(d) Current Tax Liability (Net)	185.90	61.49
	Sub-Total - Current Liabilities	41,118.35	35,297.63
	TOTAL - EQUITY AND LIABILITIES	1,46,064.80	1,36,243.92


SMS Pharmaceuticals Ltd. Hyderabad

SMS Pharmaceuticals Limited

Consolidated Statement of Cash Flow for the Half Year Ended September 30, 2026

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

S No	Particulars	for the Period Ended	
		30.09.2026 (Unaudited)	30.09.2025 (Unaudited)
A	Cash Flow from Operating Activities		
	Profit Before Tax	8,002.27	5,841.08
	Adjustments for:		
	Depreciation and Amortisation Expense	2,043.24	1,977.31
	Interest Income	(42.12)	(10.55)
	Interest on Borrowings	1,064.46	1,099.07
	Provision for Employee Benefits	69.88	(8.53)
	Amortisation of Transaction Cost on Borrowings	11.47	11.03
	Loss on Sale of Assets	0.01	-
	Unrealised Profit in Associate Company Sales	(29.45)	(64.69)
		11,119.76	8,844.72
	Change in Operating Assets and Liabilities		
	(Increase)/Decrease in Trade Receivables	(2,742.67)	(1,819.01)
	(Increase)/Decrease in Inventories	(2,653.35)	(3,273.68)
	(Increase)/Decrease in Other Non Current Financial Assets	6.78	(24.75)
	(Increase)/Decrease in Other Non Current Asset	1,590.39	(1,112.75)
	(Increase)/Decrease in Other Current Financial Assets	96.62	782.83
	(Increase)/Decrease in Other Current Assets	(454.63)	(556.02)
	Increase/(Decrease) in Trade Payables	5,002.98	2,581.63
	Increase/(Decrease) in Other Financial Liabilities	746.90	35.81
	Increase/(Decrease) in Other Current Liabilities	(359.24)	(189.17)
		1,233.78	(3,575.11)
	Cash generated from Operations	12,353.54	5,269.61
	Income Taxes Paid	(1,777.59)	(1,037.10)
	Net Cash Inflow from Operating Activities "A"	10,575.95	4,232.51
B	Cash flow from Investing Activities		
	Purchase of Property, Plant and Equipment	(8,588.19)	(2,966.71)
	Sale of Property, Plant and Equipment	1.00	-
	Investment in Deposits	(0.39)	(0.27)
	Margin Money Deposits	(5.17)	(62.60)
	Interest Received on Margin Money Deposit	48.60	(20.77)
	Net Cash Inflow (Outflow) from Investing Activities "B"	(8,544.15)	(3,050.35)
C	Cash Flow from Financing Activities		
	Proceeds from Long Term Borrowings	-	638.69
	Repayment of Long Term Borrowings	(2,599.79)	(2,196.00)
	Proceeds from Short Term Borrowings	1,031.20	2,900.98
	Interest paid on Borrowings	(1,065.19)	(1,124.25)
	Net Proceeds from issue / conversion of Share Warrants	-	4,762.07
	Dividend Paid to Company's Shareholders	(374.61)	(354.61)
	Net Cash Inflow (Outflow) from Financing Activities "C"	(3,008.39)	4,626.88
	Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)	(976.59)	5,809.04
	Cash and Cash Equivalents at the beginning of the Financial Year	4,587.70	4,139.91
	Cash and Cash Equivalents at end of the Period	3,611.11	9,948.95



Notes:

1 The above Consolidated un-audited financial results have been reviewed by the Audit Committee on November 04, 2026 and approved by the Board of Directors at their meeting held on November 04, 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued un modified conclusion in respect of the limited review for the quarter and six months ended September 30, 2026.

2 These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act,2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).

3 VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the Company holds 34.83% as on September 30, 2026 in their equity. Accordingly, the results include appropriate share of the results of said Associate.

4 The Company has joint venture namely "Chemo SMS Enterprises SL" in which there were no financial operations during the reporting period, hence, this entity is not considered for consolidation.

5 SMS coLab Private Limited, which is a wholly owned subsidiary company and SMS Peptides Private Limited, which is a subsidiary company, have incurred expenditure and assets, which have been appropriately consolidated in the financial statements for the reporting period in compliance with the applicable Indian Accounting Standards (Ind AS).

6 The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

7 As approved by the Members of the company at the 37th Annual General Meeting held on September 29, 2026, the company has disbursed on September 30, 2026 a dividend of Re.0.40 per equity share of Re.1/- each for the year ended March 31, 2026, aggregating to Rs.374.61 Lakhs.

8 The figures have been regrouped / reclassified as necessary.

Place: Hyderabad
Date : November 04, 2026

For SMS Pharmaceuticals Limited



Ramesh Babu Potluri
Chairman and Managing Director